Hoth Therapeutics Inc
NASDAQ:HOTH

Watchlist Manager
Hoth Therapeutics Inc Logo
Hoth Therapeutics Inc
NASDAQ:HOTH
Watchlist
Price: 1.04 USD -3.7% Market Closed
Market Cap: 16.1m USD

Relative Value

HOTH doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of HOTH.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HOTH Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1
Industry
21.4
Forward
-1.9
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.2
Industry
16.8
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.2
Industry
23.1
vs History
14
vs Industry
40
Median 3Y
0.8
Median 5Y
1.2
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
51
Median 3Y
0.3
Median 5Y
-0.2
Industry
13.3
vs History
vs Industry
48
Median 3Y
0.3
Median 5Y
-0.2
Industry
16.5
Forward
-0.6
vs History
vs Industry
52
Median 3Y
0.3
Median 5Y
-0.2
Industry
16
vs History
vs Industry
39
Median 3Y
0.3
Median 5Y
-0.2
Industry
18.9
vs History
39
vs Industry
11
Median 3Y
5.2
Median 5Y
2.7
Industry
2

Multiples Across Competitors

HOTH Competitors Multiples
Hoth Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Hoth Therapeutics Inc
NASDAQ:HOTH
15.7m USD 0 -1.3 -0.6 -0.6
US
Eli Lilly and Co
NYSE:LLY
982.2B USD 16.5 53.3 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
526.1B USD 5.7 20.9 17.1 22.2
CH
Roche Holding AG
SIX:ROG
277.8B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP 5 31 108.8 159.2
CH
Novartis AG
SIX:NOVN
221.8B CHF 4.9 19.2 12.1 15.7
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.6 11.6 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Hoth Therapeutics Inc
NASDAQ:HOTH
Average P/E: 25
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
19.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Hoth Therapeutics Inc
NASDAQ:HOTH
Average EV/EBITDA: 440
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Hoth Therapeutics Inc
NASDAQ:HOTH
Average EV/EBIT: 1 883.7
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.2
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.7
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5